Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ENT2 Double Nickase Plasmid (h): sc-401952-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ENT2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ENT2 Double Nickase Plasmid (h) and ENT2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLC29A2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ENT2 Antibody (D-9): sc-373871
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ENT2 Double Nickase Plasmid (h) | sc-401952-NIC | 20 µg | $410.00 | |||
ENT2 Double Nickase Plasmid (h2) | sc-401952-NIC-2 | 20 µg | $410.00 |
SLC29A2 encodes equilibrative nucleoside transporter 2 (ENT2), a broadly expressed plasma membrane transporter that mediates bidirectional, concentration-dependent flux of purine and pyrimidine nucleosides. ENT2 supports nucleoside salvage pathways that sustain nucleotide pools for DNA/RNA synthesis and contributes to cellular responses to metabolic stress by regulating extracellular and intracellular nucleoside availability. By shaping nucleoside homeostasis, ENT2 intersects with processes such as cell-cycle progression, replication stress responses, and nucleoside-dependent signaling in many tissues. Altered SLC29A2/ENT2 activity and expression have been investigated in contexts including tumor biology, immune cell function, and transporter-related variation in cellular sensitivity to nucleoside analogs, supporting its relevance for mechanistic studies.
ENT2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLC29A2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLC29A2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLC29A2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLC29A2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.